about
Characterization of HCV genotype 5a envelope proteins: implications for vaccine development and therapeutic entry target.Prediction of T-cell epitopes of hepatitis C virus genotype 5aIdentification and genetic characterization of unique HIV-1 A1/C recombinant strain in South Africa.Detection, genotyping and quantitation of multiple hpv infections in south African women with cervical squamous cell carcinoma.Hepatitis B virus infection in post-vaccination South Africa: occult HBV infection and circulating surface gene variantsMutations associated with occult hepatitis B in HIV-positive South AfricansFunctional analysis of 'a' determinant mutations associated with occult HBV in HIV-positive South Africans.Genetic characterization of HIV before widespread testing of HIV vaccine candidates at a clinical trial site in Pretoria, South Africa.Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa.Complete genome analysis of hepatitis B virus in human immunodeficiency virus infected and uninfected South Africans.Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study.Active co-infection with HBV and/or HCV in South African HIV positive patients due for cancer therapy.Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa.Near full-length genome analysis of HCV genotype 5 strains from South Africa.Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
P50
Q34864567-C0D07D15-37E6-426B-AD42-7269432210C5Q34896702-C4D2A582-EF02-4715-909C-5D204E3D5036Q35142500-42D78D86-96DD-49AC-99DF-C8E30533AEBCQ35650525-D4E88E0C-8697-43AD-950E-AFA9D08013E1Q36028735-F2960572-A5EF-4689-B9E4-BA531A75DB0FQ36035578-195D2865-FAB8-4918-92EC-FA1A8C1610F4Q38782188-96BD1BC8-C3C7-4C62-B6C3-63B2895D0434Q39284385-05C72971-2E94-4F15-8EE3-3C9D416A993CQ39312711-573189A3-F911-4511-9A4E-16738F75B5DCQ39987547-6E41CE5D-EE2E-44FE-AB08-C537BC81A201Q40651684-5EC4B4A5-D580-495C-BA96-27BD6A62CB75Q42197952-CC0AD047-2205-43CD-899B-E96B5D0A519BQ42232465-CBD0EFBE-8084-49F8-8311-2D7EEDDE6C62Q42256182-D029943A-ED2E-4A3E-AAF2-F0C58200C2ECQ44441066-1C98EF18-1A60-4564-81D5-88E7C60F238B
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-5101-5198
@en
name
Gloria Selabe
@ast
Gloria Selabe
@en
Gloria Selabe
@es
Gloria Selabe
@nl
type
label
Gloria Selabe
@ast
Gloria Selabe
@en
Gloria Selabe
@es
Gloria Selabe
@nl
prefLabel
Gloria Selabe
@ast
Gloria Selabe
@en
Gloria Selabe
@es
Gloria Selabe
@nl
P106
P1153
22036303600
P21
P31
P496
0000-0001-5101-5198